128 related articles for article (PubMed ID: 38490915)
1. Receipt of financial assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer: A prospective cohort study.
Kumar A; Ragavan M; Velazquez AI; Zeng S; Wong ML
J Geriatr Oncol; 2024 Jun; 15(5):101746. PubMed ID: 38490915
[No Abstract] [Full Text] [Related]
2. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Protsenko SA; Rudakova AV
Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs.
Giuliani J; Bonetti A
Clin Lung Cancer; 2017 Sep; 18(5):e363-e365. PubMed ID: 28502555
[No Abstract] [Full Text] [Related]
4. Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.
Adamson RT
Am J Manag Care; 2013 Dec; 19(19 Suppl):s398-404. PubMed ID: 24494721
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?
Chouaid C; Borget I; Vergnenegre A
J Clin Oncol; 2014 Nov; 32(31):3577. PubMed ID: 25199755
[No Abstract] [Full Text] [Related]
6. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies.
Korytowsky B; Radtchenko J; Nwokeji ED; Tuell KW; Kish JK; Feinberg BA
Am J Manag Care; 2018 Oct; 24(20 Suppl):S439-S447. PubMed ID: 30362811
[TBL] [Abstract][Full Text] [Related]
7. 3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
Lin CC; Hsia TC; Chien CR
Lung Cancer; 2012 Jun; 76(3):499-500. PubMed ID: 22503286
[No Abstract] [Full Text] [Related]
8. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Leighl NB; Tsao WS; Zawisza DL; Nematollahi M; Shepherd FA
Lung Cancer; 2006 Jan; 51(1):115-21. PubMed ID: 16188343
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
[TBL] [Abstract][Full Text] [Related]
10. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Chouaid C; Le Caer H; Locher C; Dujon C; Thomas P; Auliac JB; Monnet I; Vergnenegre A;
BMC Cancer; 2012 Jul; 12():301. PubMed ID: 22817667
[TBL] [Abstract][Full Text] [Related]
11. [Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer].
Kogure Y
Gan To Kagaku Ryoho; 2018 May; 45(5):781-784. PubMed ID: 30026436
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lung cancer: will financial issues become a criterion of choice?
Vergnenegre A; Borget I; Chouaid C
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):273-5. PubMed ID: 23763524
[No Abstract] [Full Text] [Related]
13. The new drugs advent: clinical or economic outcomes?
De Maio E; Perrone F; Bisagni G; Boni C
Ann Oncol; 2006 Mar; 17 Suppl 2():ii88-90. PubMed ID: 16608995
[No Abstract] [Full Text] [Related]
14. Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review.
Bearz A; Berretta M; Tirelli U
Curr Cancer Drug Targets; 2018; 18(5):405-409. PubMed ID: 28176647
[TBL] [Abstract][Full Text] [Related]
15. Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
Cohen J; Looney W
J Natl Cancer Inst; 2010 Aug; 102(15):1207; author reply 1207-10. PubMed ID: 20651322
[No Abstract] [Full Text] [Related]
16. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
[TBL] [Abstract][Full Text] [Related]
17. Genotyping lung cancer is an investment in the future.
Azzoli CG; Engelman J; Fidias P; Gainor JF; Heist RS; Lamont EB; Lennes IT; Rosovsky RP; Sequist LV; Shaw AT; Temel JS
J Clin Oncol; 2014 Nov; 32(31):3576-7. PubMed ID: 25199750
[No Abstract] [Full Text] [Related]
18. [Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].
Moldvay J
Magy Onkol; 2007; 51(3):191-6. PubMed ID: 17922058
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Use of High-Cost Agents for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Bradley CJ; Eguchi M; Perraillon MC
J Natl Cancer Inst; 2020 Aug; 112(8):802-809. PubMed ID: 31710664
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?
Kelly RJ; Hillner BE; Smith TJ
J Clin Oncol; 2014 Apr; 32(10):983-5. PubMed ID: 24567437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
